Conference Coverage
Latest News
Aug 05, 2026 | News
Trial to evaluate ivonescimab plus enfortumab vedotin in urothelial carcinoma
Pearls & Perspectives: Wearable Technology and the Future of Sexual Health, With Elliot Justin, MD
Aug 05, 2026
FDA clears Revi Extend implant for urgency urinary incontinence
Aug 05, 2026
FDA updates in urology: July 2026
Aug 04, 2026
Alan Bryce, MD, highlights key phase 3 advances in prostate cancer
Aug 04, 2026
Advertisement
Shorts
0:36
Joshua Halpern, MD, on the advantages of mail-in semen analysis
a day ago
by
Joshua Halpern, MD, MS
0:59
EV/pembro approval: Translating the science into global care
2 days ago
by
María Natalia Gandur Quiroga, MD, MSc
1:08
Janelle Bunce, PA-C, discusses a holistic approach to testosterone deficiency care
5 days ago
by
Janelle Bunce, PA-C
0:45
Matthew Galsky, MD, on the changing role of cisplatin eligibility in MIBC
6 days ago
by
Matthew Galsky, MD
0:29
Joshua Halpern, MD, on what’s next in male fertility diagnostics
7 days ago
by
Joshua Halpern, MD, MS
1:02
EV/pembro toxicity: What patients need to know upfront
8 days ago
by
María Natalia Gandur Quiroga, MD, MSc
1:33
The UroOnc Minute: Using physician data to improve patient outcomes
9 days ago
by
Adam B. Weiner, MD(+1 more)
1:07
Debra L. Fromer, MD, highlights efficacy data on tebipenem pivoxil for cUTI
12 days ago
by
Debra L. Fromer, MD
0:52
Beyond trial and error: The future of functional urology
13 days ago
by
Sasha Vereecken, RN
1:04
How the BRIDGE trial may impact bladder cancer treatment
14 days ago
by
Tyler Garman, MD
From GSM guidance to HRT reform: A landmark year for women’s health
2025 featured multiple advancements in women's health aimed at enhancing treatment options and awareness.
Inguinal lymph node dissection in penile cancer
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
Inside HoLEP: Irina Jaeger, MD, discusses patient selection and technique
Jaeger emphasizes that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication.
Podcasts
Videos
Urology Times Digital Edition
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
"The overall 0% impact to urology does not help urology practices deal with increasing costs incurred for staff, rent, supplies, and other overhead," write Jonathan Rubenstein, MD, and Mark Painter.
"If 2025 showed us anything, it is the power of combining scientific progress with public engagement," writes Michael S. Cookson, MD, MMHC, FACS.
"Once money is in a Roth IRA, the withdrawal rules depend on whether the funds are contributions, conversions, or earnings," writes Julie Khazan, CFP.
The approval is supported by results from the phase 3 KEYNOTE-905/EV-303 trial.
The ExactVu micro-ultrasound platform demonstrated noninferior detection of clinically significant prostate cancer vs MRI.
"The OBBA includes broad and sweeping changes that will have a profound impact," writes Allan Shen, CFP.
The ENDURE 1 study plans to enroll up to 60 patients with benign ureteric strictures.
The phase 3 PSMAddition trial assessed the combination of 177Lu-PSMA-617 plus ADT/ARPI in an earlier stage of metastatic prostate cancer.
Jaeger emphasized that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication
Continuing Medical Education
Advertisement
All News
Advertisement
OMCAZIO demonstrated bioequivalence to CABOMETYX at a lower dose and was found to have no clinically significant food effect.
Recent data suggest that bladder cancer burden is increasing across age groups, with a disproportionate rise among younger women.
Four Urology Times Clinical Forums show that ARPI safety, drug interactions, and cognitive effects, not efficacy alone, guide mCSPC therapy selection.
The approval is supported by data from the phase 3 PSMAddition trial.
Joshua Lang, MD, MS discusses how emerging biomarkers may help personalize treatment decisions while highlighting barriers to precision oncology in prostate cancer.
A reference on the key recommendations from the AUA Testosterone Deficiency guideline.
AI in medicine is here. What happens next matters for the future of health care delivery.
A 10-year registry analysis found focal HIFU and cryotherapy achieved durable cancer control and low prostate cancer mortality in localized disease.
In this episode, Gabe Canales reflects on his journey receiving a diagnosis of prostate cancer at a young age and emphasizes the importance of patient advocacy.
Matthew D. Galsky, MD, discusses how the FDA approval of enfortumab vedotin plus pembrolizumab for MIBC is moving the field beyond cisplatin eligibility and influencing future approaches to surgery and response-guided therapy.
Advertisement
Adanma Ayanambakkam, MD, MS, highlights data from the phase 1 FIT-001 trial evaluating darlifarnib plus cabozantinib in patients with advanced renal cell carcinoma.
This FAQ outlines the major recommendations from PCWG4 for urologists and clinical investigators involved in prostate cancer clinical trials.
Phase 3 BOND-003 data published in The Lancet Oncology showed that intravesical cretostimogene grenadenorepvec produced durable complete responses and a favorable safety profile in patients with high-risk, BCG-unresponsive NMIBC with CIS.
Experts discuss why accurately recognizing CIS in patients with suspected NMIBC is essential to preventing disease progression, guiding surveillance, and expanding treatment and clinical trial opportunities.
Darlifarnib plus cabozantinib demonstrated encouraging antitumor activity with a manageable safety profile in patients with ccRCC, including both cabozantinib-naive and cabozantinib-exposed populations.
Advertisement
Advertisement
Trending on Urology Times
1
Alan Bryce, MD, highlights key phase 3 advances in prostate cancer
2
FDA updates in urology: July 2026
3
FDA grants tentative approval to new cabozantinib capsule formulation
4
FDA clears Revi Extend implant for urgency urinary incontinence
5